MAP plots funding route to US Levadex launch
This article was originally published in Scrip
MAP Pharmaceuticals appears optimistic about its chances of winning US FDA approval for Levadex (dihydroergotamine) after receiving a complete response letter (CRL) from the agency earlier this year, since the company has initiated a common stock offering to raise $52 million that it plans to spend on commercialising its inhaled migraine therapy.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.